Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0040822 (tremor)
 18,428 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A woman in her late 40s with a 5 year history of anxiety was treated with relaxation training and cognitive restructuring. Her anxiety was manifested by facial twitching, hand fidgeting, vocal tremor, loss of self-esteem, and depression. Therapy seemed to reduce motor symptoms and improve her self-esteem, confidence, and mood. Six months after the start of therapy the client was found to have Meige's Disease. Following treatment with botulinum toxin, motor symptoms disappeared. This case highlights the need for psychotherapists to be more aware of neurological and medical problems which may mimic psychological ones.
 ...
PMID:Meige's disease misdiagnosed as anxiety disorder. 180 56

We evaluated prospectively 100 patients, the largest reported series, with blepharospasm and orofacial-cervical dystonia, or Meige syndrome. The mean age at onset was 51.7 years, and 81% presented between the ages of 40 and 70. Women outnumbered men three to two. Blepharospasm was the initial symptom in 58 patients, but only 23 had involuntary movements localized to the orbicularis oculi. Sixty-one patients had the complete syndrome, blepharospasm and oromandibular dystonia, and 60 had neck or generalized dystonia in addition to the orofacial movements. Twenty-one patients with spasmodic dysphonia were included; in 12 of these patients, spasmodic dysphonia was part of the complete (Meige) syndrome, and 16 of these patients had neck or generalized dystonia or essential tremor. An organic cause of Meige syndrome is supported by a high correlation with essential tremor and other movement disorders and by positive family history in some patients. Response to medication was inconsistent, but 69% of patient trials resulted in some improvement; in 22% the benefit was marked and persistent. Tetrabenazine, lithium, and trihexyphenidyl were most useful for the treatment of oromandibular dystonia, and clonazepam was useful in some patients with blepharospasm.
 ...
PMID:Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. 683 74

Drug-induced tardive motor syndromes (TMS) is a group of disorders, characterized by involuntary movements of the tongue, face, lips, trunk and extremities, occurring after long-term exposure to a variety of pharmacological agents, mostly neuroleptics. The diagnosis of TMS requires exposure to dopamine receptor blocking agents for a period at least of 3 months, although for people over 60 years old the necessary exposure period is limited to 1 month. The exact pathophysiology still remains obscure. The aim of this article is to review the phenomenology, epidemiology and treatment options of the TMS, as clinically distinct movement disorders. TMS include tardive dyskinesia, which is the most common movement disorder, tardive dystonia, tardive akathisia, tardive Tourettism, tardive tremor and tardive myoclonus as well as some specific syndromes less often presented such as Pisa, Meige and Rabbit syndromes. Prevention remains the cornerstone in good clinical practice. Preventive approach requires thorough diagnostic process with frequent reviews in order to determine the necessity of use and dosing of neuroleptic treatment. Clinical vigilance for early detection of signs of TMS as well as recording of early extrapyramidal side-effects in the patient's history is needed, as these may predict the occurrence of TMS. In case of occurrence of TMS, gradual discontinuation of the offending agent is required. Therapeutic interventions include the administration of the following agents: atypical antipsychotics (mainly clozapine), benzodiazepines, vitamin E, reserpine, tetrabenazine, anticholinergics, botulinum toxin A. The early management of TMS is crucial for the patients' better clinical outcome and improved quality of life.
 ...
PMID:Drug-induced tardive motor syndromes. 2246 75